Detailed Narrative
Q2 Financial Outperformance and Strategic Progress
Option Care Health reported Q2 FY26 revenue of $1.4 billion, adjusted EBITDA of $117.5 million, and adjusted EPS of $0.45, all exceeding internal expectations. This performance reflects strong operational execution and the positive impact of 2026 strategic initiatives. The company also generated $184 million in operating cash flow and repurchased $150 million in stock, reinforcing its commitment to disciplined capital allocation and shareholder returns.
Acute and Chronic Portfolio Dynamics
The acute therapy portfolio continued its strong organic growth in the high single digits, driven by deepening partnerships with hospitals and health systems. Within the chronic platform, the IG/neuro and rare and orphan portfolios delivered solid sequential and year-over-year revenue growth. The chronic inflammatory disease (CID) portfolio began to stabilize, with patient census rising sequentially after a Q1 reset, and is expected to grow further through the remainder of the year.
Strategic Initiatives and Technology Investment
Management highlighted significant progress on initiatives to sharpen execution, improve competitiveness, and resume growth. These include strengthening the commercial team, enhancing go-to-market strategies, and improving operational effectiveness. The company is also investing in AI, digital tools, workflow automation, and advanced analytics to improve care coordination, reduce administrative complexity, and enhance patient and provider experience, with benefits expected to build through H2 2026 and into 2027.
Ambulatory Infusion Clinic Expansion
Option Care Health expanded its ambulatory infusion clinic footprint by adding 5 new facilities in Q2. Utilization of these facilities increased, with visits growing over 20% year-over-year. The company leverages its network of infusion suites, conducting over 35% of nursing visits in these facilities, reinforcing clinic-based growth as an important complement to its pharmacy model and driving performance through deeper local provider partnerships.
STELARA Biosimilar Impact and Future Outlook
The company reiterated that its 2026 full-year revenue and gross profit projections incorporate approximately 600 basis points of year-over-year revenue headwind and a $55 million gross profit headwind from the CID portfolio, primarily due to STELARA and related biosimilars, which are expected to represent less than 1% of 2026 net revenue and gross profit. Management expressed confidence in building momentum through the back half of the year and into 2027, driven by core business strength and strategic initiatives.
Capital Allocation and Shareholder Returns
The company remains committed to its capital allocation strategy, prioritizing organic investments to drive revenue growth, capacity, and cost structure optimization. This is followed by returning capital to shareholders through periodic share buybacks; the $150 million share repurchase in Q2 reduced the remaining authorization to $525 million. Potential acquisitions focusing on adjacencies and tuck-ins that align with the portfolio breadth are also evaluated.
Medicare Coverage Expansion Proposal
Management commented on CMS's proposed expansion of Medicare coverage for certain home infusion pumps and drugs starting in 2027. While seen as a positive step for expanding market access and demonstrating the value of home-based care in reducing total costs, the impact is not expected to be significantly material due to the narrow scope of therapies covered. The company continues to advocate for broader access.